Abstract
S-1 (TS-1®)-related studies presented at the 74th Japanese Gastric Cancer Congress are reviewed. Of the papers presented at this conference, 35 were related to S-1. In the panel discussion on the therapeutic significance of oral fluoropyrimidines in gastric cancer, 9 papers were related to S-1 (sensitivities to oral fluoropyrimidines, 2 papers; clinical results of treatment with S-1, 5 papers; and combination therapy with S-1, 2 papers). In the general presentations, there were 26 papers on S-1 related-subjects (clinical studies or clinical practice of S-1, 12 papers; case reports, 3 papers; basic studies on animal models of peritoneal metastasis, 2 papers; and combination therapy with S-1, 9 papers). Several studies showed that S-1 was basically as effective against tumors in postmarketing surveillance in clinical practice as in phase II studies at the time of its development, including a report of a patient with complete response to S-1. Some reports suggested the possibility of using S-1 in neoadjuvant chemotherapy and postoperative adjuvant chemotherapy. The usefulness of S-1 in combination chemotherapy was also suggested in several reports. These results indicate that S-1 is a key drug that can be used in first-line treatment of gastric cancer. It will be necessary to accumulate evidence based on data from clinical trials and clinical applications in the future.
Article PDF
Similar content being viewed by others
References
T Shirasaka K Nakano T Takechi H Satake J Uchida A Fujioka et al. (1996) ArticleTitleAntitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydropyrimidine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted in nude rat Cancer Res 56 2602–6 Occurrence Handle8653704 Occurrence Handle1:CAS:528:DyaK28XjtlCgurg%3D
T Shirasaka Y Simamoto Y Fukushima (1993) ArticleTitleInhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats Cancer Res 53 4004–9 Occurrence Handle7689420 Occurrence Handle1:CAS:528:DyaK3sXmtFKqsrk%3D
M Fukushima H Satake J Uchida Y Shimamoto T Kato T Takechi et al. (1998) ArticleTitlePreclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts Int J Oncol 13 693–8 Occurrence Handle9735397 Occurrence Handle1:CAS:528:DyaK1cXmsVClurw%3D
T Kato Y Shimamoto J Uchida H Ohshimo M Abe T Shirasaka et al. (2001) ArticleTitlePossible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulations consisting of S-1, a new oral formulation of 5-fluorouracil Anticancer Res 21 1705–12 Occurrence Handle11497250 Occurrence Handle1:CAS:528:DC%2BD3MXmt1eru7g%3D
T Shirasaka Y Shimamoto H Ohshima M Yamaguchi T Kato K Yonemura M Fukushima (1996) ArticleTitleDevelopment of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 548–57 Occurrence Handle8862723 Occurrence Handle1:CAS:528:DyaK28Xltleru78%3D
Y Sakata A Ohtsu N Horikoshi Y Sugimachi Y Mitachi T Taguchi (1998) ArticleTitleLate phase II study of novel oral fluoropyrimidine anticancer drugs S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715–20 Occurrence Handle9893658 Occurrence Handle10.1016/S0959-8049(98)00211-1 Occurrence Handle1:CAS:528:DyaK1cXntlShurw%3D
W Koizumi M Kurihara S Nakano K Hasegawa (2000) ArticleTitlePhase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer Oncology 58 191–7 Occurrence Handle10765119 Occurrence Handle10.1159/000012099 Occurrence Handle1:CAS:528:DC%2BD3cXjvVeitr4%3D
A Ohtsu N Boku F Nagashima W Koizumi S Tanabe K Saigenji et al. (2001) ArticleTitleA phase I/II study of S-1 plus cisplatin (CDDP) in patients (pts) with advanced gastric cancer (ACG) Proc Am Soc Clin Oncol 20 165a
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sasaki, T. Current topics of S-1 at the 74th Japanese Gastric Cancer Congress. Gastric Cancer 6 (Suppl 1), 9–12 (2003). https://doi.org/10.1007/s10120-003-0229-4
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10120-003-0229-4